Biotech Drug Report Generated Aug 18, 2026

Neladalkib

GSK·GSK plc

BULLISH

Drug Impact Rating6/10

Trial Phase: Filed/PDUFA (NDA under FDA Priority Review)
Time to Market: If approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.
Why 6/10: The next hard, dated catalyst is the FDA PDUFA target action date of November 27, 2026 for neladalkib in TKI pre-treated advanced ALK-positive NSCLC (Priority Review) — a ~3-month binary on a strategically important asset, but one of many programs inside a ~$100B market-cap pharma, so the share-price move on GSK should be modest.

Actionable Insight ▲ BULLISH

For GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured — Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.

Price Chart

Loading chart...

Executive Summary

Neladalkib is Nuvalent's late-stage ALK-inhibitor pill for TKI pre-treated advanced ALK-positive non-small cell lung cancer. Its NDA was submitted to the FDA in May 2026 and accepted with Priority Review; the PDUFA target action date is November 27, 2026. GSK plc agreed on June 9, 2026 to buy Nuvalent for $124.00 per share in cash (~$10.6 billion total equity value, ~40% premium), and the merger closed July 15, 2026, so the drug now belongs to GSK's oncology franchise alongside ROS1 drug zidesamtinib (PDUFA September 18, 2026) and phase I HER2 asset NVL-330.

How It Works

An oral pill that blocks ALK, a protein that drives the growth of a subset of non-small cell lung cancers (ALK-positive NSCLC). It is a next-generation ALK inhibitor aimed at patients whose cancer has already progressed on earlier ALK-targeting drugs (the 'TKI pre-treated' population), where tumors often develop resistance mutations.

Trial Status

Nuvalent submitted the NDA to the FDA (reported May 2026, disclosed April 7, 2026); FDA accepted the NDA and granted Priority Review with a PDUFA target action date of November 27, 2026 for TKI pre-treated advanced ALK-positive non-small cell lung cancer. No approval action is on record yet, and no confirmatory Phase 3 readout appears in ingested trial data — the filing rests on the earlier-stage clinical program.

The Two-Sided Case

▲ Bull Case4

FDA accepted the NDA with Priority Review and set a PDUFA target action date of November 27, 2026 — a fast-tracked regulatory path for TKI pre-treated advanced ALK-positive NSCLC (local FDA-catalyst records, e.g. catalyst row dated 2026-08-05).

GSK paid $124.00/share in cash, a total equity value of approximately $10.6 billion and a ~40% premium to last close, for Nuvalent's lung-cancer assets — heavy conviction in neladalkib and its sibling zidesamtinib (GSK 6-K/8-K reports, June 2026).

Targets an unmet-need patient group — ALK-positive NSCLC that has already progressed on prior tyrosine kinase inhibitors — where resistance to older ALK drugs is a well-known problem (SEC catalyst records list the indication as TKI pre-treated advanced ALK-positive NSCLC).

Deal already closed July 15, 2026 at $124.00/share, so the takeover-premium upside is banked; for GSK the asset is additive to a franchise GSK's own filing analysis described as having multi-blockbuster potential (GSK 6-K analysis, July 2026).

▼ Bear Case5

Approval is not assured: the November 27, 2026 PDUFA is a binary, and no confirmatory Phase 3 readout appears in the ingested trial data — the NDA is based on the earlier-stage program, leaving room for a CRL or additional-data requirements.

For GSK shareholders the impact is diluted: GSK is a ~$100B market-cap diversified pharma (per market snapshot in GSK 6-K, 2026-08-18), so one oncology NDA — win or lose — is a modest single-asset catalyst, not a make-or-break event.

GSK itself guided to low single-digit EPS dilution through FY2028 from the Nuvalent deal, with accretion only by 2029 — the acquisition weighs on near-term earnings (GSK 6-K report, June 2026).

Competition: ALK-positive NSCLC is a crowded, established market with existing ALK inhibitors from large pharma; neladalkib must win in the pretreated segment and, longer term, fight for earlier lines.

NUVL equity no longer exists — the stock was delisted after the July 15, 2026 merger close (Form 15-12G, July 27, 2026), so there is no direct single-asset equity vehicle left for this drug.

Upcoming Catalysts

November 27, 2026: FDA PDUFA target action date for neladalkib in TKI pre-treated advanced ALK-positive NSCLC (Priority Review).
September 18, 2026: PDUFA for franchise sibling zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC — a read-through on how FDA treats the Nuvalent filings (reported in Nuvalent Q1 2026 and FY2025 earnings events).
Any FDA Advisory Committee meeting, CRL/approval communications, or confirmatory-trial design updates before the PDUFA.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 8

Hover a chip for the title

1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov7 sec.gov8 sec.gov